/ Not yet recruitingNot Applicable A Phase II study of MGCD0103 (MG-0103) in patients with acute myelogenous leukemia/high risk MDS who are elderly and have previously untreated disease or who are adult and have relapsed/refractory disease
/ Not yet recruitingNot Applicable Randomised, Controlled, Open-Label, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma
100 Clinical Results associated with Pharmion GmbH
0 Patents (Medical) associated with Pharmion GmbH
100 Deals associated with Pharmion GmbH
100 Translational Medicine associated with Pharmion GmbH